{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:31:52Z","timestamp":1793475112712,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11918"],"award-info":[{"award-number":["24K11918"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10388-026-01245-9","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:31:24Z","timestamp":1787805084000},"page":"879-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of combining circulating tumor DNA and endoscopic response evaluation for esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Yuki","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-2755","authenticated-orcid":false,"given":"Satoru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiso","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"1245_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404:55\u201366.","journal-title":"Lancet"},{"key":"1245_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20:343\u201372.","journal-title":"Esophagus"},{"key":"1245_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 2. Esophagus. 2023;20:373\u201389.","journal-title":"Esophagus"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","volume":"149","author":"E Ghisoni","year":"2021","unstructured":"Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153\u201364.","journal-title":"Eur J Cancer"},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.critrevonc.2018.07.002","volume":"129","author":"CRP da Veiga","year":"2018","unstructured":"da Veiga CRP, da Veiga CP, Drummond-Lage AP. Concern over cost of and access to cancer treatments: a meta-narrative review of nivolumab and pembrolizumab studies. Crit Rev Oncol Hematol. 2018;129:133\u201345.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/cancers17020196","volume":"17","author":"Y Hoshi","year":"2025","unstructured":"Hoshi Y, Matsuda S, Takeuchi M, Kawakubo H, Kitagawa Y. Liquid biopsy and multidisciplinary treatment for esophageal cancer. Cancers (Basel). 2025;17:196.","journal-title":"Cancers (Basel)"},{"key":"1245_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.","journal-title":"J Hematol Oncol"},{"key":"1245_CR11","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1245\/s10434-023-13194-z","volume":"30","author":"Y Morimoto","year":"2023","unstructured":"Morimoto Y, Matsuda S, Kawakubo H, Nakamura K, Kobayashi R, Hisaoka K, et al. Tumor burden monitoring with circulating tumor DNA during treatment in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2023;30:3747\u201356.","journal-title":"Ann Surg Oncol"},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"109625","DOI":"10.1016\/j.ejso.2025.109625","volume":"51","author":"R Kobayashi","year":"2025","unstructured":"Kobayashi R, Matsuda S, Nakamura K, Kawakubo H, Ho K, Morimoto Y, et al. Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2025;51:109625.","journal-title":"Eur J Surg Oncol"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1245\/s10434-021-11009-7","volume":"29","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Kawakubo H, Tsuji T, Aoyama J, Hirata Y, Takemura R, et al. Clinical significance of endoscopic response evaluation to predict the distribution of residual tumor after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2022;29:2673\u201380.","journal-title":"Ann Surg Oncol"},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374.","journal-title":"Ann Surg Oncol"},{"key":"1245_CR15","doi-asserted-by":"crossref","unstructured":"Rice TW, Patil DT, Blackstone EH. 8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119\u201330.","DOI":"10.21037\/acs.2017.03.14"},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.1002\/cam4.3383","volume":"9","author":"K Saotome","year":"2020","unstructured":"Saotome K, Chiyoda T, Aimono E, Nakamura K, Tanishima S, Nohara S, et al. Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors. Cancer Med. 2020;9:7407\u201317.","journal-title":"Cancer Med"},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"btac830","DOI":"10.1093\/bioinformatics\/btac830","volume":"39","author":"JT Robinson","year":"2023","unstructured":"Robinson JT, Thorvaldsdottir H, Turner D, Mesirov JP. igv.js: An embeddable JavaScript implementation of the integrative genomics viewer (IGV). Bioinformatics. 2023;39:btac830.","journal-title":"Bioinformatics"},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1\u201336.","journal-title":"Esophagus"},{"key":"1245_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10388-016-0556-2","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus. 2017;14:37\u201365.","journal-title":"Esophagus"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/anticanres.14746","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Lai Yau TH, Sideris M. Chemoradiotherapy in cancer treatment: rationale and clinical applications. Anticancer Res. 2021;41:1\u20137.","journal-title":"Anticancer Res"},{"key":"1245_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","volume":"114","author":"H Takeuchi","year":"2022","unstructured":"Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114:454\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1245_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(25)00027-0","volume":"26","author":"BJ van der Wilk","year":"2025","unstructured":"van der Wilk BJ, Eyck BM, Wijnhoven BPL, Lagarde SM, Rosman C, Noordman BJ, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2025;26:425\u201336.","journal-title":"Lancet Oncol"},{"key":"1245_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2023.08.010","volume":"34","author":"K Nilsson","year":"2023","unstructured":"Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023;34:1015\u201324.","journal-title":"Ann Oncol"},{"key":"1245_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.2022.40.4_suppl.286","volume":"40","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)\u2014short-term results for cohorts C and D. J Clin Oncol. 2022;40:286\u2013286.","journal-title":"J Clin Oncol"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2024.42.3_suppl.326","volume":"42","author":"T Yoshii","year":"2024","unstructured":"Yoshii T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)\u2014primary safety and short-term efficacy results for cohort E. J Clin Oncol. 2024;42:326\u2013326.","journal-title":"J Clin Oncol"},{"key":"1245_CR26","doi-asserted-by":"publisher","first-page":"TPS474","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS474","volume":"41","author":"S Tsunoda","year":"2023","unstructured":"Tsunoda S, Tsubosa Y, Sasaki K, Machida R, Daiko H, Kato K, et al. A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: a phase III trial (JCOG2013, MODERN3). J Clin Oncol. 2023;41:TPS474\u2013474.","journal-title":"J Clin Oncol"},{"key":"1245_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00268-012-1822-7","volume":"37","author":"T Yasuda","year":"2013","unstructured":"Yasuda T, Yano M, Miyata H, Yamasaki M, Takiguchi S, Fujiwara Y, et al. Evaluation of dysphagia and diminished airway protection after three-field esophagectomy and a remedy. World J Surg. 2013;37:416\u201323.","journal-title":"World J Surg"},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox096","volume":"30","author":"K Yamashita","year":"2017","unstructured":"Yamashita K, Makino T, Yamasaki M, Tanaka K, Hara T, Miyazaki Y, et al. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus. 2017;30:1\u20138.","journal-title":"Dis Esophagus"},{"key":"1245_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jphys.2016.08.008","volume":"62","author":"P Kent","year":"2016","unstructured":"Kent P, Hancock MJ. Interpretation of dichotomous outcomes: sensitivity, specificity, likelihood ratios, and pre-test and post-test probability. J Physiother. 2016;62:231\u20133.","journal-title":"J Physiother"},{"key":"1245_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10388-025-01130-x","volume":"22","author":"S Matsuda","year":"2025","unstructured":"Matsuda S, Irino T, Kitagawa Y, Okamura A, Mayanagi S, Booka E, et al. Detection of pathologic complete response using deep neural network-based endoscopic evaluation in patients with esophageal cancer receiving neoadjuvant chemotherapy: a nationwide multicenter retrospective study from 46 Japanese esophageal centers. Esophagus. 2025;22:322\u201330.","journal-title":"Esophagus"},{"key":"1245_CR31","doi-asserted-by":"publisher","unstructured":"Takei S, Kotani D, Laliotis G, Sato K, Fujiwara N, Kawazoe A, et al. Circulating tumor DNA assessment to predict risk of recurrence after surgery in patients with locally advanced esophageal squamous cell carcinoma: a prospective observational study. Ann Surg. 2025. https:\/\/doi.org\/10.1097\/SLA.0000000000006699","DOI":"10.1097\/SLA.0000000000006699"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01245-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01245-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01245-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:17:15Z","timestamp":1793474235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01245-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s10388-026-01245-9","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the Institutional Review Board of Keio University School of Medicine (IRB no. 20190057), and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.","order":1,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kitagawa Y received research grants from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., KAKEN PHARMACEUTICAL CO., LTD., Sumitomo Pharma Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Kowa Company, Ltd, and Terumo Corporation. Kitagawa Y received personal fees from ASAHI KASEI PHARMA CORPORATION, TAIHO PHARMACEUTICAL CO., LTD., CHUGAI PHARMACEUTICAL CO., LTD., KAKEN PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., Ethicon Inc., ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Factory, Inc., Olympus Corporation, Cardinal Health K.K., SHIONOGI & CO., LTD., Bristol-Myers Squibb K.K., MSD K.K., ASKA Pharmaceutical Co., Ltd., MIYARISAN PHARMACEUTICAL CO. LTD., Toray Industries, Inc., DAIICHI SANKYO COMPANY, LIMITED, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku Co., Ltd., EA Pharma Co., Ltd., Intuitive Surgical G.K., Takeda Pharmaceutical Company Limited, SYSMEX CORPORATION, TSUMURA & CO., AI Medical Service Inc., and Eisai Co., Ltd. Kitagawa Y received financial support from SYSMEX CORPORATION and Medicaroid Corporation for Joint Research Laboratory for Development and Education of Innovative Medical Technology. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}